Major depression and anxiety are highly prevalent and involve chronic dysregulation of
serotonin, but they remain poorly understood. Here, we review novel transcriptional (genetic …

Depression, an emotion regulation disorder, is a prevalent mental illness in the world.
Meanwhile, traditional Chinese medicine (TCM) has been increasingly regarded as a …

To date, there are no biomarkers for major depressive disorder (MDD) treatment response in
clinical use. Such biomarkers could allow for individualized treatment selection, reducing …

Chronic treatment with fluoxetine (FLX) is required for its antidepressant effects, but the role
of serotonin (5-HT) axonal plasticity in FLX action is unknown. To address this, we examined …

Neuroplasticity involves synaptic reorganization (Box 1) in response to environmental
stressors or rewards and is thought to underlie our ability to adjust, learn and remember. 7 …

Depression is a complex psychiatric disorder influenced by various genetic and
environmental factors. Strong evidence has established the contribution of genetic factors in …

Heterogeneity within Major Depressive Disorder (MDD) has hampered identification of
biological markers (eg, intermediate phenotypes, IPs) that might increase risk for the …

BackgroundReported childhood adversity (CA) is associated with development of
depression in adulthood and predicts a more severe course of illness. Although elevated …

Objective Little is known about the relationship between antidepressant treatment outcomes
and underlying neurobiological mechanisms in patients with major depressive disorder …

Abstract Background Central serotonin (5-hydroxytryptamine [5-HT]) neurotransmission has
been implicated in the etiology of depression. Most antidepressants ameliorate depressive …